Researchers Innovate CAR T Therapy for Relapsed Leukemia Patients

Recent advancements in cancer treatment have emerged as researchers from the Institute of Process Engineering at the Chinese Academy of Sciences unveiled a new biomimetic platform that enhances the efficacy of chimeric antigen receptor T (CAR T) cell therapy for patients suffering from relapsed and refractory leukemia. This innovative approach could significantly improve outcomes for individuals who have not responded to traditional CAR T treatments.

CAR T therapy has marked a significant milestone in leukemia treatment, as it involves genetically engineering a patient’s T cells to target specific antigens on leukemia cells. Despite its promise, clinical data indicate that over 50% of patients experience a relapse post-treatment. One major contributing factor to this relapse is the ability of leukemia cells to diminish or lose expression of the targeted antigens under therapeutic pressure, rendering CAR T cells ineffective.

In a departure from previous strategies that involved complex genetic modifications, the researchers developed a platform that does not require any genetic alterations to CAR T cells. Their findings, published in the journal Cell on March 9, 2026, highlight the potential of this biomimetic approach to address the limitations of current CAR T therapies.

The team collaborated with Zhujiang Hospital and the Institute of Hematology & Blood Diseases Hospital to analyze a wide range of clinical samples. Their research identified that CD71, a protein responsible for iron transport, is highly expressed on leukemia cells across various types and stages of the disease, as well as on the CAR T cells themselves. This discovery led to the development of a ferritin aggregation cell engager (FACE), which acts as a molecular “bridge” enhancing interactions between CAR T cells and leukemia cells.

During the preparation of CAR T cells, FACE binds to CD71 on the surface of these cells. Following infusion, FACE connects CAR T cells to leukemia cells, bolstering their capacity to recognize and eliminate the cancerous cells. In patient-derived xenograft (PDX) models with normal antigen expression, FACE-enhanced CAR T cells delivered comparable therapeutic effects to conventional CAR T cells while utilizing only one-fifth of the cell dose. This reduction notably decreases the risk of cytokine release syndrome, a common complication associated with CAR T therapy.

Even in scenarios where leukemia antigen levels dropped below 10% of normal, conditions that typically hinder conventional CAR T efficacy, FACE-CAR T cells demonstrated a remarkable ability to eliminate leukemia cells, achieving a survival rate of 100% in PDX models. The researchers further developed a drug-loaded version of FACE, known as FACED, which capitalized on ferritin’s cage-like structure. FACED-CAR T cells were effective in treating PDX models with an initial leukemia burden of up to 40%, even in cases of low antigen expression.

The simplicity and scalability of the FACE platform, composed of endogenous proteins and FDA-approved polymer derivatives, allow for seamless integration into existing CAR T cell manufacturing processes. The system can be co-incubated with CAR T cells prior to infusion, eliminating the need for additional genetic engineering.

Prof. WEI Wei, the corresponding author of the study, emphasized the practical implications of this research, stating, “Our FACE platform can be prepared through a simple and scalable process, making it suitable for current clinical workflows.”

Prof. MA Guanghui from IPE added, “By systematically evaluating FACE across diverse patient-derived leukemia samples and clinically relevant PDX models, we demonstrated its broad applicability across disease subtypes and treatment-resistant settings.”

The study has garnered attention from peer reviewers at Cell, who described the findings as “highly relevant to the CAR T field” and a “promising translational approach” to improving responses against hematologic malignancies. The reviewers highlighted the potential of this strategy to address the heterogeneity of leukemia antigens while avoiding the complexities associated with additional genetic engineering.

In summary, this pioneering study offers a compelling biomimetic platform that enhances CAR T cell performance through improved cell engagement and targeted drug delivery. With robust preclinical validation, the FACE strategy presents a practical and innovative solution for improving outcomes in patients with relapsed and refractory leukemia.